Literature DB >> 9024704

Sphincter preservation therapy for distal rectal carcinoma: a review.

A K Ng1, A Recht, P M Busse.   

Abstract

BACKGROUND: There has been increasing interest in the use of sphincter-preserving therapy for patients with distal rectal carcinomas. The outcomes of conservative treatments for early stage rectal carcinoma appear to be comparable to that achieved with abdominoperineal resection.
METHODS: Retrospective and prospective clinical series of patients with distal rectal carcinoma treated by local excision alone, local excision with postoperative adjuvant therapy, preoperative radiation followed by local excision, or radical circumferential sphincter-sparing surgeries were reviewed. The local control rates, salvage rates, and treatment complications in patients treated by these various methods were examined.
RESULTS: Patients with T1 distal rectal carcinoma with favorable clinical and histopathologic characteristics treated with local excision alone had a local control rate of greater than 90% in most series. Postoperative chemoradiation improved local control for those with T1 disease with unfavorable characteristics, or those with T2 disease. Most T3 patients had failure rates of greater than 30% despite adjuvant local and systemic therapy. With high dose preoperative radiation, approximately 80% of patients with locally advanced or unresectable tumors were able to undergo sphincter-preservation treatment.
CONCLUSIONS: Patients with favorable T1 rectal carcinoma are likely to be adequately treated with local excision alone. Patients with T1 disease with unfavorable characteristics as well as T2 patients will benefit from postoperative chemoradiation. The use of local therapy in T3 patients needs to be carefully considered because these patients are at relatively high risk for local recurrence despite adjuvant therapy. Preoperative radiation followed by either local excision or radical circumferential sphincter-sparing resections appears promising in allowing sphincter preservation in patients with locally advanced tumors.

Entities:  

Mesh:

Year:  1997        PMID: 9024704     DOI: 10.1002/(sici)1097-0142(19970215)79:4<671::aid-cncr3>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Treatment of stage II-III rectal cancer patients.

Authors:  Miranda B Kim; Theodore S Hong; Jennifer Y Wo
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

Review 2.  Laparoscopically assisted transsacral resection of rectal cancer with primary anastomosis. A preliminary review.

Authors:  D W Weaver; S R Eachempati
Journal:  Surg Endosc       Date:  2000-08       Impact factor: 4.584

Review 3.  Sphincter preservation in rectal cancer.

Authors:  C G Willett
Journal:  Curr Treat Options Oncol       Date:  2000-12

4.  Hospital factors and patient characteristics in the treatment of colorectal cancer: a population based study.

Authors:  Carlotta Sacerdote; Ileana Baldi; Oscar Bertetto; Daniela Dicuonzo; Enzo Farina; Eva Pagano; Rosalba Rosato; Carlo Senore; Franco Merletti; Giovannino Ciccone
Journal:  BMC Public Health       Date:  2012-09-12       Impact factor: 3.295

5.  Neo-adjuvant chemoradiotherapy; an opportunity in sphincter preserving procedure for rectal cancer.

Authors:  Mohammad Mozafar; Farideh Adhami; Khashayar Atqiaee; Saran Lotfollahzadeh; Mohammad Reza Sobhiyeh; Razie Amraei; Maryam Baikpour
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2014
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.